Epidemiological and Economic Evaluation of a Pilot Prostate Cancer Screening Program

Table 6

Prostate cancer screening costs in the Pavlodar region in 2017.

Stages/year	1 Stage of screening			2 Stage of screening			3 Stage of screening			4 Stage of screening			Total KZT (thousand)
	Number of target patients aged 50, 54, 58, 62, 66 for total PSA	Sum per 1 patient, KZT	Total sum, KZT (thousand)	Number of patients for free & ProPSA (4%)	Sum per 1 patient, KZT	Total sum, KZT (thousand)	Number of patients for biopsy (3%)	Sum per 1 patient, KZT	Total sum, KZT (thousand)	Number of patients for histology (3%)	Sum per 1 patient, KZT	Total sum, KZT (thousand)
Total	9638	1323,42	12755	145	27625,05	4006	145	6561,0	951	145	2348,7	2724	20437
-value	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
1 Stage	9638	1323,42	12755										12755,1
Venous blood sampling	9638	134,02	1292										1291,7
Total PSA levels testing	9638	1189,4	11463										11463,4
2 Stage				145	27625,05	4006							4005,6
Total PSA levels testing				145	1189,4	172							172,5
Free PSA levels testing				145	2091,05	303							303,2
Pro-PSA levels testing				145	24344,6	3530							3530,0
3 Stage							145	6561,00	951				951,3
Urologist consultation							145	770,85	112				111,8
Transrectal Ultrasonography of the Prostate							145	673,71	98				97,7
Prostate Biopsy							145	5116,44	742				741,9
4 Stage										145	2348,67	2724	2724,5
Histological evaluation										145	2348,67	2724	2724,5

test of difference. ANOVA. The chi square test is only valid for comparing the number of patients at the first stage of screening with subsequent screening stages. We did not compare the subsequent screening stages between each other as these are the same observations.